{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:00:13Z","timestamp":1788886813192,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS079198"],"award-info":[{"award-number":["NS079198"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA211015 CEP"],"award-info":[{"award-number":["P50CA211015 CEP"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11060-025-05200-z","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:49:39Z","timestamp":1755067779000},"page":"1079-1089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells"],"prefix":"10.1007","volume":"175","author":[{"given":"Matthew Z.","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Treger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Imbroane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Orpilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungjun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Reynoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Vitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Liau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Everson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"5200_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2012\u20132016. Neurooncology 21:v1\u2013v100. https:\/\/doi.org\/10.1093\/neuonc\/noz150","journal-title":"Neurooncology"},{"key":"5200_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11060-009-9934-0","volume":"95","author":"A Durand","year":"2009","unstructured":"Durand A, Labrousse F, Jouvet A et al (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neuro-oncol 95:367\u2013375. https:\/\/doi.org\/10.1007\/s11060-009-9934-0","journal-title":"J Neuro-oncol"},{"key":"5200_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","volume":"24","author":"WL Bi","year":"2021","unstructured":"Bi WL, Nayak L, Meredith DM et al (2021) Activity of PD-1 Blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neurooncology 24:101\u2013113. https:\/\/doi.org\/10.1093\/neuonc\/noab118","journal-title":"Neurooncology"},{"key":"5200_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3389\/fneur.2020.00945","volume":"11","author":"T Garzon-Muvdi","year":"2020","unstructured":"Garzon-Muvdi T, Bailey DD, Pernik MN, Pan E (2020) Basis for immunotherapy for treatment of meningiomas. Front Neurol 11:945. https:\/\/doi.org\/10.3389\/fneur.2020.00945","journal-title":"Front Neurol"},{"key":"5200_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-019-02342-8","volume":"68","author":"YD Li","year":"2019","unstructured":"Li YD, Veliceasa D, Lamano JB et al (2019) Systemic and local immunosuppression in patients with high-grade meningiomas. Cancer Immunol Immunother 68:999\u20131009. https:\/\/doi.org\/10.1007\/s00262-019-02342-8","journal-title":"Cancer Immunol Immunother"},{"key":"5200_CR6","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.18632\/oncotarget.27994","volume":"12","author":"JW Rutland","year":"2021","unstructured":"Rutland JW, Dullea JT, Shrivastava RK (2021) Future directions for immunotherapy in meningioma treatment. Oncotarget 12:2300\u20132301. https:\/\/doi.org\/10.18632\/oncotarget.27994","journal-title":"Oncotarget"},{"key":"5200_CR7","doi-asserted-by":"publisher","first-page":"noab168","DOI":"10.1093\/neuonc\/noab168","volume":"23","author":"M Terabe","year":"2021","unstructured":"Terabe M, Wu J (2021) Rethinking immunotherapy in meningiomas. Neurooncology 23:noab168. https:\/\/doi.org\/10.1093\/neuonc\/noab168","journal-title":"Neurooncology"},{"key":"5200_CR8","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.18632\/oncotarget.4694","volume":"6","author":"MF Gjerstorff","year":"2015","unstructured":"Gjerstorff MF, Andersen MH, Ditzel HJ (2015) Oncogenic cancer\/testis antigens: prime candidates for immunotherapy. Oncotarget 6:15772\u201315787. https:\/\/doi.org\/10.18632\/oncotarget.4694","journal-title":"Oncotarget"},{"key":"5200_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers11070984","volume":"11","author":"G Al-Khadairi","year":"2019","unstructured":"Al-Khadairi G, Decock J (2019) Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME? Cancers 11:984. https:\/\/doi.org\/10.3390\/cancers11070984","journal-title":"Cancers"},{"key":"5200_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/2326-6066.cir-13-0029","volume":"1","author":"GS Baia","year":"2013","unstructured":"Baia GS, Caballero OL, Ho JS et al (2013) NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches. Cancer Immunol Res 1:296\u2013302. https:\/\/doi.org\/10.1158\/2326-6066.cir-13-0029","journal-title":"Cancer Immunol Res"},{"key":"5200_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J et al (2018) NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 9:947. https:\/\/doi.org\/10.3389\/fimmu.2018.00947","journal-title":"Front Immunol"},{"key":"5200_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/jco.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917\u2013924. https:\/\/doi.org\/10.1200\/jco.2010.32.2537","journal-title":"J Clin Oncol"},{"key":"5200_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport AP, Stadtmauer EA, Binder-Scholl GK et al (2015) NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21:914\u2013921. https:\/\/doi.org\/10.1038\/nm.3910","journal-title":"Nat Med"},{"key":"5200_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","volume":"7","author":"I Ramachandran","year":"2019","unstructured":"Ramachandran I, Lowther DE, Dryer-Minnerly R et al (2019) Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer 7:276. https:\/\/doi.org\/10.1186\/s40425-019-0762-2","journal-title":"J Immunother Cancer"},{"key":"5200_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/neuonc\/nov153","volume":"18","author":"RG Everson","year":"2016","unstructured":"Everson RG, Antonios JP, Lisiero DN et al (2016) Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neurooncology 18:368\u2013378. https:\/\/doi.org\/10.1093\/neuonc\/nov153","journal-title":"Neurooncology"},{"key":"5200_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1479-5876-9-192","volume":"9","author":"VV Konkankit","year":"2011","unstructured":"Konkankit VV, Kim W, Koya RC et al (2011) Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the fas\/fas ligand pathway. J Transl Med 9:192\u2013192. https:\/\/doi.org\/10.1186\/1479-5876-9-192","journal-title":"J Transl Med"},{"key":"5200_CR17","doi-asserted-by":"publisher","first-page":"e0178322","DOI":"10.1371\/journal.pone.0178322","volume":"12","author":"Y Mei","year":"2017","unstructured":"Mei Y, Bi WL, Greenwald NF et al (2017) Genomic profile of human meningioma cell lines. PLoS ONE 12:e0178322. https:\/\/doi.org\/10.1371\/journal.pone.0178322","journal-title":"PLoS ONE"},{"key":"5200_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3171\/jns.1995.82.5.0864","volume":"82","author":"J-C Tsai","year":"1995","unstructured":"Tsai J-C, Goldman CK, Gillespie GY (1995) Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82:864\u2013873. https:\/\/doi.org\/10.3171\/jns.1995.82.5.0864","journal-title":"J Neurosurg"},{"key":"5200_CR19","unstructured":"Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenblum ML (1993) Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 15;53(10 Suppl):2386\u20132392. PMID: 8485725."},{"key":"5200_CR20","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1158\/1078-0432.ccr-05-0464","volume":"11","author":"LM Liau","year":"2005","unstructured":"Liau LM, Prins RM, Kiertscher SM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515\u20135525. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-0464","journal-title":"Clin Cancer Res"},{"key":"5200_CR21","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.4049\/jimmunol.180.9.6116","volume":"180","author":"PF Robbins","year":"2008","unstructured":"Robbins PF, Li YF, El-Gamil M et al (2008) Single and dual amino acid substitutions in TCR CDRs can enhance Antigen-Specific T cell functions. J Immunol 180:6116\u20136131. https:\/\/doi.org\/10.4049\/jimmunol.180.9.6116","journal-title":"J Immunol"},{"key":"5200_CR22","doi-asserted-by":"publisher","unstructured":"Hamidi H, Lilja J, Ivaska J (2017) Using xCELLigence RTCA instrument to measure cell adhesion. BIO-Protoc 7:https:\/\/doi.org\/10.21769\/bioprotoc.2646.","DOI":"10.21769\/bioprotoc.2646"},{"key":"5200_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s10544-013-9790-8","volume":"15","author":"G Ramis","year":"2013","unstructured":"Ramis G, Mart\u00ednez-Alarc\u00f3n L, Quereda JJ et al (2013) Optimization of cytotoxicity assay by real-time, impedance-based cell analysis. Biomed Microdevices 15:985\u2013995. https:\/\/doi.org\/10.1007\/s10544-013-9790-8","journal-title":"Biomed Microdevices"},{"key":"5200_CR24","doi-asserted-by":"publisher","first-page":"e17990","DOI":"10.1097\/md.0000000000017990","volume":"98","author":"H Wang","year":"2019","unstructured":"Wang H, Chen D, Wang R et al (2019) NY-ESO-1 expression in solid tumors predicts prognosis. Medicine 98:e17990. https:\/\/doi.org\/10.1097\/md.0000000000017990","journal-title":"Medicine"},{"key":"5200_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ijc.28752","volume":"135","author":"S Laban","year":"2014","unstructured":"Laban S, Atanackovic D, Luetkens T et al (2014) Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer 135:1142\u20131152. https:\/\/doi.org\/10.1002\/ijc.28752","journal-title":"Int J Cancer"},{"key":"5200_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3171\/jns.1968.29.3.0283","volume":"29","author":"M Abbott","year":"1968","unstructured":"Abbott M, Killeffer FA, Crandall PH (1968) Melanotic meningioma: case report. J Neurosurg 29:283\u2013286. https:\/\/doi.org\/10.3171\/jns.1968.29.3.0283","journal-title":"J Neurosurg"},{"key":"5200_CR27","first-page":"231","volume":"5","author":"T Backer-Gr\u00f8ndahl","year":"2012","unstructured":"Backer-Gr\u00f8ndahl T, Moen BH, Torp SH (2012) The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 5:231\u2013242","journal-title":"Int J Clin Exp Pathol"},{"key":"5200_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jnen\/nlab053","volume":"80","author":"C-HG Lucas","year":"2021","unstructured":"Lucas C-HG, Devine P, Solomon DA et al (2021) Sarcomatous meningioma: diagnostic pitfalls and the utility of molecular testing. J Neuropathol Exp Neurol 80:764\u2013768. https:\/\/doi.org\/10.1093\/jnen\/nlab053","journal-title":"J Neuropathol Exp Neurol"},{"key":"5200_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/archopht.116.9.1241","volume":"116","author":"RE Warwar","year":"1998","unstructured":"Warwar RE, Bullock JD, Shields JA, Eagle RC (1998) Coexistence of 3 tumors of neural crest origin: neurofibroma, meningioma, and uveal malignant melanoma. Arch Ophthalmol 116:1241\u20131243. https:\/\/doi.org\/10.1001\/archopht.116.9.1241","journal-title":"Arch Ophthalmol"},{"key":"5200_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2217\/cns-2016-0005","volume":"5","author":"M Lucchesi","year":"2016","unstructured":"Lucchesi M, Buccoliero AM, Scoccianti S et al (2016) A successful case of an anaplastic meningioma treated with chemotherapy for soft tissue sarcomas. CNS Oncol 5:131\u2013136. https:\/\/doi.org\/10.2217\/cns-2016-0005","journal-title":"CNS Oncol"},{"key":"5200_CR31","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S (2023) TCR-engineered T cell therapy in solid tumors: state of the Art and perspectives. Sci Adv 9:eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700","journal-title":"Sci Adv"},{"key":"5200_CR32","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.4081\/ejh.2022.3377","volume":"66","author":"K Hashimoto","year":"2022","unstructured":"Hashimoto K, Nishimura S, Ito T et al (2022) Clinicopathological assessment of cancer\/testis antigens NYESO-1 and MAGEA4 in osteosarcoma. Eur J Histochem 66:3377. https:\/\/doi.org\/10.4081\/ejh.2022.3377","journal-title":"Eur J Histochem"},{"key":"5200_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41422-022-00639-5","volume":"32","author":"C Zhou","year":"2022","unstructured":"Zhou C, Ma L, Xu H et al (2022) Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity. Cell Res 32:543\u2013554. https:\/\/doi.org\/10.1038\/s41422-022-00639-5","journal-title":"Cell Res"},{"key":"5200_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","volume":"577","author":"E Song","year":"2020","unstructured":"Song E, Mao T, Dong H et al (2020) VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 577:689\u2013694. https:\/\/doi.org\/10.1038\/s41586-019-1912-x","journal-title":"Nature"},{"key":"5200_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.adc8810","volume":"379","author":"K M\u00f8llg\u00e5rd","year":"2023","unstructured":"M\u00f8llg\u00e5rd K, Beinlich FRM, Kusk P et al (2023) A mesothelium divides the subarachnoid space into functional compartments. Science 379:84\u201388. https:\/\/doi.org\/10.1126\/science.adc8810","journal-title":"Science"},{"key":"5200_CR36","doi-asserted-by":"publisher","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS et al (2018) Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma. Cancer Discov 8. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-1417:CD-17-1417","DOI":"10.1158\/2159-8290.cd-17-1417"},{"key":"5200_CR37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.ccr-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013Reactive T-cell receptor: Long-term Follow-up and correlates with response. Clin Cancer Res 21:1019\u20131027. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2708","journal-title":"Clin Cancer Res"},{"key":"5200_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/s0198-8859(99)00155-x","volume":"61","author":"JM Ellis","year":"2000","unstructured":"Ellis JM, Henson V, Slack R et al (2000) Frequencies of HLA-A2 alleles in five U.S. Population groups predominance of A\u221702011 and identification of HLA-A\u22170231. Hum Immunol 61:334\u2013340. https:\/\/doi.org\/10.1016\/s0198-8859(99)00155-x","journal-title":"Hum Immunol"},{"key":"5200_CR39","doi-asserted-by":"publisher","first-page":"e2338612","DOI":"10.1001\/jamanetworkopen.2023.38612","volume":"6","author":"T Olivier","year":"2023","unstructured":"Olivier T, Haslam A, Tuia J, Prasad V (2023) Eligibility for human leukocyte Antigen\u2013Based therapeutics by race and ethnicity. JAMA Netw Open 6:e2338612. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.38612","journal-title":"JAMA Netw Open"},{"key":"5200_CR40","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C et al (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro-Oncol 25:iv1\u2013iv99. https:\/\/doi.org\/10.1093\/neuonc\/noad149","journal-title":"Neuro-Oncol"},{"key":"5200_CR41","doi-asserted-by":"publisher","first-page":"e006930","DOI":"10.1136\/jitc-2023-006930","volume":"11","author":"L Frankiw","year":"2023","unstructured":"Frankiw L, Singh A, Peters C et al (2023) Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to Transgenic adoptive cellular therapy with PD-1 Blockade. J Immunother Cancer 11:e006930. https:\/\/doi.org\/10.1136\/jitc-2023-006930","journal-title":"J Immunother Cancer"},{"key":"5200_CR42","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/2767-9764.crc-23-0566","volume":"4","author":"TJ Lai","year":"2024","unstructured":"Lai TJ, Sun L, Li K et al (2024) Epigenetic induction of cancer-Testis antigens and endogenous retroviruses at Single-Cell level enhances immune recognition and response in glioma. Cancer Res Commun 4:1834\u20131849. https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0566","journal-title":"Cancer Res Commun"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05200-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05200-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05200-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:14:02Z","timestamp":1759994042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05200-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5200"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05200-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article has been revised: Except for the first author\u2019s affiliations, all the other authors\u2019 affiliations have been corrected (from UTSW to UCLA).","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}